These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 31821389)

  • 1. [CHEK1 expression and inhibitors in TP53 mutant cancer].
    Õsz Á; Aszódi B; Vajda R; Keserû MG; Moll HP; Casanova E; Gyõrffy B
    Magy Onkol; 2019 Dec; 63(4):345-352. PubMed ID: 31821389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Checkpoint Kinase 1 Expression Predicts Poor Prognosis in Nigerian Breast Cancer Patients.
    Ebili HO; Iyawe VO; Adeleke KR; Salami BA; Banjo AA; Nolan C; Rakha E; Ellis I; Green A; Agboola AOJ
    Mol Diagn Ther; 2018 Feb; 22(1):79-90. PubMed ID: 29075961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN.
    Regina S; Valentin JB; Lachot S; Lemarié E; Rollin J; Gruel Y
    Clin Chem; 2009 Oct; 55(10):1834-42. PubMed ID: 19661141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
    Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
    Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
    VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
    Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells.
    Gali-Muhtasib H; Kuester D; Mawrin C; Bajbouj K; Diestel A; Ocker M; Habold C; Foltzer-Jourdainne C; Schoenfeld P; Peters B; Diab-Assaf M; Pommrich U; Itani W; Lippert H; Roessner A; Schneider-Stock R
    Cancer Res; 2008 Jul; 68(14):5609-18. PubMed ID: 18632613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated analysis of the prognostic value of TP53 dependent etoposide-induced gene 24 in non-small cell lung cancer.
    Wang M; Li P; Wan R; Liu X
    Biomed Pharmacother; 2019 Apr; 112():108590. PubMed ID: 30784913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer.
    Alcaraz-Sanabria A; Nieto-Jiménez C; Corrales-Sánchez V; Serrano-Oviedo L; Andrés-Pretel F; Montero JC; Burgos M; Llopis J; Galán-Moya EM; Pandiella A; Ocaña A
    Mol Cancer Ther; 2017 Nov; 16(11):2552-2562. PubMed ID: 28847989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
    Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
    Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
    Jiao XD; Qin BD; You P; Cai J; Zang YS
    Lung Cancer; 2018 Sep; 123():70-75. PubMed ID: 30089598
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
    World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
    van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
    Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 7-Hydroxystaurosporine (UCN-01) preferentially sensitizes cells with a disrupted TP53 to gamma radiation in lung cancer cell lines.
    Xiao HH; Makeyev Y; Butler J; Vikram B; Franklin WA
    Radiat Res; 2002 Jul; 158(1):84-93. PubMed ID: 12071807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.
    Langerød A; Zhao H; Borgan Ø; Nesland JM; Bukholm IR; Ikdahl T; Kåresen R; Børresen-Dale AL; Jeffrey SS
    Breast Cancer Res; 2007; 9(3):R30. PubMed ID: 17504517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma.
    Liu DH; Zhao ZR; Lin YB; Zhou WJ; Hou JY; Ye ZH; Long H
    Ann Surg Oncol; 2019 Jun; 26(6):1934-1941. PubMed ID: 30820786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of TP53 mutations on the prognosis of patients with early stage non-small cell lung cancer may depend on the intratumor heterogeneity of the mutations.
    Lee SY; Jeon HS; Hwangbo Y; Jeong JY; Park JY; Lee EJ; Jin G; Shin KM; Yoo SS; Lee J; Lee EB; Cha SI; Kim CH; Park JY
    Mol Carcinog; 2015 Feb; 54(2):93-101. PubMed ID: 24038464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
    Pfaff E; Remke M; Sturm D; Benner A; Witt H; Milde T; von Bueren AO; Wittmann A; Schöttler A; Jorch N; Graf N; Kulozik AE; Witt O; Scheurlen W; von Deimling A; Rutkowski S; Taylor MD; Tabori U; Lichter P; Korshunov A; Pfister SM
    J Clin Oncol; 2010 Dec; 28(35):5188-96. PubMed ID: 21060032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
    Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
    Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.